| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -201,977 | -111,190 | -45,629 | -74,546 |
| Amortization of investment premiums | 7,553 | 5,524 | 3,133 | 13,236 |
| Amortization of financing costs | 56 | 48 | 24 | 70 |
| Stock-based compensation | 32,231 | 24,895 | 11,348 | 24,045 |
| Amortization of right-of-use assets | 337 | 223 | 111 | 236 |
| Realized (gain) loss on investment | 14 | 4 | - | 111 |
| Interest expense related to operating lease liability | 26 | 18 | 10 | 27 |
| Prepaid expenses and other current assets | 19,477 | 14,643 | 9,554 | 1,059 |
| Accrued interest, net of interest receivable on maturity of investments | -4,663 | -2,459 | -2,470 | -1,845 |
| Accounts payable | -5,400 | -4,319 | -2,110 | -7,258 |
| Accrued expenses | 4,102 | 8,904 | -5,739 | 13,652 |
| Lease liability | -389 | -259 | -129 | -274 |
| Net cash used in operating activities | -193,395 | -99,392 | -52,331 | -56,609 |
| Purchases of investments | 377,544 | 356,090 | 232,614 | 976,408 |
| Proceeds from maturities of investments | 643,320 | 461,841 | 295,859 | 416,458 |
| Net cash provided by (used in) investing activities | 265,776 | 105,751 | 63,245 | -559,950 |
| Public offering, net of offering costs | 0 | 0 | - | -597,094 |
| Value of shares withheld related to employee tax withholding | 0 | 0 | - | 42,101 |
| Proceeds from exercises of stock options and other stock issuances | 1,336 | 856 | 349 | 9,813 |
| Atm offering, net of fees | 0 | 0 | - | 46,658 |
| Net cash provided by financing activities | 1,336 | 856 | 349 | 611,464 |
| Net increase (decrease) in cash and cash equivalents | 73,717 | 7,215 | 11,263 | -5,095 |
| Cash and cash equivalents at beginning of period | 26,676 | 26,676 | 26,676 | 55,516 |
| Effect of exchange rate changes on cash | -17 | -11 | 1 | -74 |
| Cash and cash equivalents at end of period | 100,376 | 33,880 | 37,940 | 50,347 |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)